109 related articles for article (PubMed ID: 38749554)
1. Cardiovascular toxicity of immune therapies for cancer.
Palaskas NL; Ali HJ; Koutroumpakis E; Ganatra S; Deswal A
BMJ; 2024 May; 385():e075859. PubMed ID: 38749554
[TBL] [Abstract][Full Text] [Related]
2. Cardiotoxicities of novel cancer immunotherapies.
Stein-Merlob AF; Rothberg MV; Ribas A; Yang EH
Heart; 2021 Nov; 107(21):1694-1703. PubMed ID: 33722826
[TBL] [Abstract][Full Text] [Related]
3. Update on Immunotherapy Cardiotoxicity: Checkpoint Inhibitors, CAR T, and Beyond.
Patel M; Hudson O; Han J; Kondapalli L; Arora G; Hawi R; Andrikopoulou E; Estes C; Johnson AM; Lenneman C
Curr Treat Options Oncol; 2023 Nov; 24(11):1489-1503. PubMed ID: 37624557
[TBL] [Abstract][Full Text] [Related]
4. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
5. Challenges and solutions in management of cardiotoxicity induced by checkpoint inhibitors.
Mladosievičová B; Országhová Z; Jablonická M; Rečková M; Chovanec M; Mego M
Klin Onkol; 2020; 33(5):350-355. PubMed ID: 33108879
[TBL] [Abstract][Full Text] [Related]
6. Potentially fatal complications of new systemic anticancer therapies: pearls and pitfalls in their initial management.
Kovac MB; Seruga B
Radiol Oncol; 2024 Jun; 58(2):170-178. PubMed ID: 38613842
[TBL] [Abstract][Full Text] [Related]
7. Cardiotoxicity associated with immune checkpoint inhibitors and CAR T-cell therapy.
Lipe DN; Rajha E; Wechsler AH; Gaeta S; Palaskas NL; Alhajji Z; Viets-Upchurch J; Chaftari P
Am J Emerg Med; 2021 Dec; 50():51-58. PubMed ID: 34274878
[TBL] [Abstract][Full Text] [Related]
8. Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors.
Baik AH; Tsai KK; Oh DY; Aras MA
Clin Sci (Lond); 2021 Mar; 135(5):703-724. PubMed ID: 33686402
[TBL] [Abstract][Full Text] [Related]
9. Cardiovascular toxicities associated with immune checkpoint inhibitors.
Hu JR; Florido R; Lipson EJ; Naidoo J; Ardehali R; Tocchetti CG; Lyon AR; Padera RF; Johnson DB; Moslehi J
Cardiovasc Res; 2019 Apr; 115(5):854-868. PubMed ID: 30715219
[TBL] [Abstract][Full Text] [Related]
10. Cardiotoxicity of Immune Checkpoint Inhibitors.
Patel RP; Parikh R; Gunturu KS; Tariq RZ; Dani SS; Ganatra S; Nohria A
Curr Oncol Rep; 2021 May; 23(7):79. PubMed ID: 33937956
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint inhibitor cardiotoxicity: Breaking barriers in the cardiovascular immune landscape.
Zhu H; Ivanovic M; Nguyen A; Nguyen PK; Wu SM
J Mol Cell Cardiol; 2021 Nov; 160():121-127. PubMed ID: 34303670
[TBL] [Abstract][Full Text] [Related]
12. Mechanisms of Cardiovascular Toxicities Associated With Immunotherapies.
Baik AH; Oluwole OO; Johnson DB; Shah N; Salem JE; Tsai KK; Moslehi JJ
Circ Res; 2021 May; 128(11):1780-1801. PubMed ID: 33934609
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Toxicity Associated With Immune Checkpoint Inhibitor Therapy: A Comprehensive Review.
Chitsazan M; Amin A; Ladel L; Baig A; Chitsazan M
Crit Pathw Cardiol; 2023 Sep; 22(3):69-82. PubMed ID: 37363862
[TBL] [Abstract][Full Text] [Related]
14. Cardiotoxicity of immune checkpoint inhibitors: An updated review.
Behravesh S; Shomali N; Danbaran GR; Aslani S; Hemmatzadeh M; Hosseinzadeh R; Gowhari-Shabgah A; Mohammadi H
Biotechnol Appl Biochem; 2022 Feb; 69(1):61-69. PubMed ID: 33289168
[TBL] [Abstract][Full Text] [Related]
15. What the Cardiologist Needs to Know About Cancer Immunotherapies and Complications.
Frayberg M; Yung A; Zubiri L; Zlotoff DA; Reynolds KL
Curr Treat Options Oncol; 2021 May; 22(6):53. PubMed ID: 34037918
[TBL] [Abstract][Full Text] [Related]
16. Immune Checkpoint Inhibitors (ICIs)-Related Cardiotoxicity.
Zarifa A; Lopez-Mattei J; Palaskas N; Iliescu C; Durand JB; Kim PY
Adv Exp Med Biol; 2020; 1244():277-285. PubMed ID: 32301022
[TBL] [Abstract][Full Text] [Related]
17. Cardiovascular Effects of Immune Checkpoint Inhibitors: More Than Just Myocarditis.
Inno A; Tarantini L; Parrini I; Spallarossa P; Maurea N; Bisceglia I; Silvestris N; Russo A; Gori S
Curr Oncol Rep; 2023 Jul; 25(7):743-751. PubMed ID: 37017825
[TBL] [Abstract][Full Text] [Related]
18. Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T).
Alvi RM; Frigault MJ; Fradley MG; Jain MD; Mahmood SS; Awadalla M; Lee DH; Zlotoff DA; Zhang L; Drobni ZD; Hassan MZO; Bassily E; Rhea I; Ismail-Khan R; Mulligan CP; Banerji D; Lazaryan A; Shah BD; Rokicki A; Raje N; Chavez JC; Abramson J; Locke FL; Neilan TG
J Am Coll Cardiol; 2019 Dec; 74(25):3099-3108. PubMed ID: 31856966
[TBL] [Abstract][Full Text] [Related]
19. New Insights into Mechanisms of Immune Checkpoint Inhibitor-Induced Cardiovascular Toxicity.
Khunger A; Battel L; Wadhawan A; More A; Kapoor A; Agrawal N
Curr Oncol Rep; 2020 Jun; 22(7):65. PubMed ID: 32514647
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy-Associated Cardiotoxicity of Immune Checkpoint Inhibitors and Chimeric Antigen Receptor T Cell Therapy: Diagnostic and Management Challenges and Strategies.
Stein-Merlob AF; Rothberg MV; Holman P; Yang EH
Curr Cardiol Rep; 2021 Jan; 23(3):11. PubMed ID: 33483873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]